Quick follow-up on something I promised I'd track: remember when I said my review of the Galleri test was coming this month? Well, the FDA just moved the story along for me. Grail's stock jumped after the agency's staff reviewers said they found no major concerns about the accuracy or safety of its blood test built to detect more than 50 cancers (Reuters has the details).

Backing up for anyone who missed the earlier piece. Galleri is a liquid biopsy, meaning it looks for fragments of tumor DNA floating around in a regular blood draw. One tube of blood, screened for dozens of cancer types at once, including ones like pancreatic and ovarian where we currently have no decent screening test at all. That's the pitch anyway.

So what actually happened? Before an advisory panel meets, FDA staff put together their own review of the company's data, and this week's document came back without any big red flags on accuracy or safety. The stock rallied on the news. Just to be clear about what this is: not approval. It's the staff's homework ahead of the panel discussion, and it's a genuinely good sign that the reviewers aren't finding problems with the core data. Panel members can still poke holes, and the FDA doesn't have to follow their recommendation anyway.

Why do I care so much about this one? Because I've written before that catching cancer early beats any fancy new drug, and I'll keep saying it. The five-year survival numbers for stage 1 versus stage 4 cancers aren't even close. The real hurdle has always been that too few high-risk people get screened, and a bunch of the deadliest cancers have no screening pathway at all. A single blood draw that flags a signal across 50 cancers changes the math for people who would otherwise find out way too late.

My mom, who is an actual doctor and not just a guy who used to eat gas station food for dinner, has a term for this that I like: a screening test is only as good as its false positive rate. That's the tension with multi-cancer detection. Screen for 50 cancers at once and you need to be really sure that a positive result leads somewhere real, because a false positive means follow-up scans, biopsies, and weeks of anxiety that nobody asked for. The staff reviewers apparently didn't see accuracy problems serious enough to write home about, which is reassuring on exactly that front, but the fuller picture comes from the panel and whatever the FDA decides after.

I'll keep my usual guardrails up. Promising data doesn't always become an approved product. I said the same thing about the AstraZeneca lung drug and the CAR-T trial, and I'll say it here too. A stock rallying is not a regulatory green light.

But between you and me? I want this one to work. A one-tube screen for the cancers we currently have no way of catching early would be a massive deal for regular people with regular schedules who aren't going to chase down five separate screening appointments. I'll be watching the advisory panel and I'll report back.